new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors




Count Application # Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
12016014402505/26/16  new patent  Methods and formulations for treating vascular eye diseases
22016014402905/26/16  new patent  Anti-erbb3 antibodies and uses thereof
32016014564605/26/16  new patent  Methods and compositions for targeted genetic modification using paired guide rnas
42016013774505/19/16 Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
52016013774605/19/16 Methods for treating high cardiovascular risk patients with hypercholesterolemia
62016013032005/12/16 Modified chimeric polypeptides with improved pharmacokinetic properties
72016012094105/05/16 Methods of using il-1 antagonists to treat alzheimer's disease
82016012243305/05/16 Anti-pdgfr-beta antibodies and uses thereof
92016011524604/28/16 Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
102016011548604/28/16 Nuclease-mediated dna assembly
112016011550204/28/16 Novel cho integration sites and uses thereof
122016010836004/21/16 Genetic modification of rats
132016010836904/21/16 Methods and compositions for generating or maintaining pluripotent cells
142016010056104/14/16 Non-human animals with modified immunoglobulin heavy chain sequences
152016010115204/14/16 Use of a vegf antagonist to treat angiogenic eye disorders
162016010118104/14/16 Process for reducing subvisible particles in a pharmaceutical formulation
172016010214704/14/16 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
182016009705904/07/16 Enhanced expression and stability regions
192016009041003/31/16 Fucosylation-deficient cells
202016008131403/24/16 Chimeric antigen receptors
212016008346603/24/16 Anti-il-25 antibodies and uses thereof
222016007577203/17/16 Treatment of fibrodysplasia ossificans progressiva
232016007577803/17/16 Anti-glucagon antibodies and uses thereof
242016005797903/03/16 Human lambda light chain mice
252016006035903/03/16 Human lambda light chain mice
262016006065703/03/16 Methods and compositions for the targeted modification of a genome
272016005089602/25/16 Non-human animals having a humanized signal-regulatory protein gene
282016005298602/25/16 Humanized il-7 rodents
292016005328002/25/16 Efficient selectivity of recombinant proteins
302016004556602/18/16 Angiopoietin-based interventions for treating cerebral malaria
312016004696002/18/16 Methods and compositions for targeted genetic modifications and methods of use
322016003059102/04/16 Biologically active molecules, conjugates thereof, and therapeutic uses
332016003201502/04/16 Stabilized formulations containing anti-pcsk9 antibodies
342016003353002/04/16 Isolating cells expressing secreted proteins
352016002185601/28/16 Genetically modified t cell receptor mice
362016002414701/28/16 Purification platform for bispecific antibodies
372016002419501/28/16 Human antibodies to grem1
382016002420801/28/16 Human antibodies to nav1.7
392016001702901/21/16 Stabilized formulations containing anti-ngf antibodies
402016000757901/14/16 Humanized dipeptidyl peptidase iv (dpp4) animals
412016000233201/07/16 Anti-asic1 antibodies and uses thereof
422016000234101/07/16 Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
432015037626712/31/15 Human antibodies to human delta like ligand 4
442015037626912/31/15 Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
452015037662812/31/15 Nuclease-mediated dna assembly
462015037665012/31/15 Methods and compositions for modifying a targeted locus
472015037665112/31/15 Methods and compositions for targeted genetic modifications and methods of use
482015036617412/24/15 Non-human animals having a humanized programmed cell death 1 gene
492015036617512/24/15 Humanized il-15 animals
502015035137112/10/15 Hybrid light chain mice
512015035137212/10/15 Humanized dipeptidyl peptidase iv (dpp4) animals
522015035363412/10/15 Production cell line enhancers
532015034216312/03/15 Genetically modified major histocompatibility complex mice
542015033702911/26/15 Human antibodies to middle east respiratory syndrome - coronavirus spike protein
552015033704311/26/15 Anti-egfr antibodies and uses thereof
562015033704511/26/15 Human antibodies to the glucagon receptor
572015032752411/19/15 Genetically modified non-human animals expressing human epo
582015033099811/19/15 Vegf-a121 assay
592015033099911/19/15 Vegf-a121 assay
602015032002111/12/15 Humanized il-4 and il-4ra animals
612015032002211/12/15 Humanized il-4 and il-4ra animals
622015032002311/12/15 Human lambda light chain mice
632015031319311/05/15 Common light chain mouse
642015031319411/05/15 Humanized c5 and c3 animals
652015031319511/05/15 Low affinity fcgr deficient mice
662015029930310/22/15 Human antibodies to fel d1 and methods of use thereof
672015029930910/22/15 Production cell line enhancers
682015029931010/22/15 Production cell line enhancers
692015028948910/15/15 Non-human animals that make single domain binding proteins
702015029197810/15/15 Mirna-regulated differentiation-dependent self-deleting cassette
712015028246310/08/15 Non-human animals having humanized fc-gamma receptors
722015028447410/08/15 Anti-pcsk9 antibodies with ph-dependent binding characteristics
732015027209210/01/15 Humanized il-6 and il-6 receptor
742015026695709/24/15 Anti-prokineticin receptor (prokr) antibodies and uses thereof
752015026696609/24/15 Methods and antibody compositions for tumor treatment
762015026697609/24/15 Vl antigen binding proteins exhibiting distinct binding characteristics
772015025942309/17/15 Anti-egfrviii antibodies and uses thereof
782015025015109/10/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
792015025210709/10/15 Aplnr modulators and uses thereof
802015024559809/03/15 Genetically modified major histocompatibility complex animals
812015024611909/03/15 Methods for treating or preventing asthma by administering an il-4r antagonist
822015024697309/03/15 Methods for treating skin infection by administering an il-4r antagonist
832015024697609/03/15 Hybrid light chain mice
842015024697709/03/15 Hybrid light chain mice
852015023123608/20/15 Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
862015023254508/20/15 Human antibodies to human delta like ligand 4
872015020862207/30/15 Genetically modified non-human animals and methods of use thereof
882015021077607/30/15 Adam6 mice
892015020158907/23/15 Adam6 mice
902015020357907/23/15 Human antibodies to pd-1
912015020358007/23/15 Human antibodies to pd-l1
922015020359107/23/15 Mutivalent antigen-binding proteins
932015019601507/16/15 Mice that make heavy chain antibodies
942015019755307/16/15 Mice that make heavy chain antibodies
952015019755407/16/15 Mice that make heavy chain antibodies
962015019755507/16/15 Mice that make heavy chain antibodies
972015019755607/16/15 Mice that make heavy chain antibodies
982015019755707/16/15 Mice that make heavy chain antibodies
992015019756407/16/15 Anti-angptl3 antibodies and uses thereof
1002015019757807/16/15 Anti-tie2 antibodies and uses thereof
1012015019153407/09/15 Human antibodies to human delta like ligand 4
1022015017333106/25/15 Human lambda light chain mice
1032015017333206/25/15 Human lambda light chain mice
1042015017567606/25/15 Fusion polypeptides capable of activating receptors
1052015017568806/25/15 Production cell line enhancers
1062015017600206/25/15 Human lambda light chain mice
1072015016559806/18/15 Devices and methods for facilitating treatment of electrospray columns
1082015016664706/18/15 Antikine antibodies that bind to multiple cc chemokines
1092015016021506/11/15 Isolating cells expressing secreted proteins
1102015015217706/04/15 High affinity human antibodies to human angiopoietin-2
1112015015219106/04/15 Dosing regimens for use with pcsk9 inhibitors
1122015014734205/28/15 Methods for treating cancer by administering an anti-ang-2 antibody
1132015014000205/21/15 Use of a pcsk9 inhibitor to treat hyperlipidemia
1142015014355805/21/15 Non-human animals having a humanized b-cell activating factor gene
1152015014355905/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
1162015014356105/21/15 Non-human animals having a humanized b-cell activating factor gene
1172015014356205/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
1182015011955604/30/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1192015011075404/23/15 High resolution allele identification
1202015011080104/23/15 Human antibodies to gfr alpha 3 and methods of use thereof
1212015010573504/16/15 Syringe pistons, systems and methods
1222015010696104/16/15 Humanized il-15 animals
1232015009929604/09/15 Promoter-regulated differentiation-dependent self-deleting cassette
1242015010003004/09/15 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1252015008967803/26/15 Non-human animals having a humanized signal-regulatory protein gene
1262015008967903/26/15 Non-human animals having a humanized signal-regulatory protein gene
1272015008968003/26/15 Human lambda light chain mice
1282015007908703/19/15 Vegf antagonist formulations
1292015008246903/19/15 Humanized il-7 rodents
1302015006418903/05/15 Method of treating cancer with dll4 antagonist and chemotherapeutic agent
1312015006790103/05/15 Production of fertile xy female animals from xy es cells
1322015005622102/26/15 Anti-prlr antibodies and uses thereof
1332015005622202/26/15 Anti-prlr antibodies and uses thereof
1342015005900902/26/15 Methods for making fully human bispecific antibodies using a common light chain
1352015004706102/12/15 Humanized m-csf mice
1362015004706202/12/15 Lincrna-deficient non-human animals
1372015003733902/05/15 Anti-activin a antibodies and uses thereof
1382015004025302/05/15 Genetically modified major histocompatibility complex mice
1392015002441201/22/15 Humanized fcgammar mice
1402015001717601/15/15 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
1412015001718201/15/15 Methods for treating nasal polyposis by administering an il-4r antagonist
1422015002022401/15/15 Non-human animals with modified immunoglobulin heavy chain sequences
1432015001056801/08/15 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1442015001302201/08/15 Humanized il-6 and il-6 receptor
1452015001302301/08/15 Humanized il-6 and il-6 receptor
1462014035637012/04/14 Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
1472014035637112/04/14 Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1482014035637212/04/14 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
1492014033134011/06/14 Methods and compositions for generating a mouse
1502014032221510/30/14 Methods of inhibiting tumor growth by antagonizing il-6 receptor
1512014031524910/23/14 Inducible eukaryotic expression system
1522014028987609/25/14 Mice that make heavy chain antibodies
1532014027164209/18/14 Il-33 antagonists and uses thereof
1542014027165309/18/14 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
1552014027165809/18/14 Anti-il-33 antibodies and uses thereof
1562014027168109/18/14 High affinity human antibodies to human il-4 receptor
1572014027309509/18/14 Serum-free cell culture medium
1582014027548909/18/14 Apelin fusion proteins and uses thereof
1592014028315809/18/14 Rodents with conditional acvr1 mutant alleles
1602014025539009/11/14 Method of treating rheumatoid arthritis with an anti-il-6r antibody
1612014025541909/11/14 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1622014025542909/11/14 Methods of treating autoimmune diseases with dll4 antagonists
1632014025599509/11/14 High affinity antibodies to human il-6 receptor
1642014024866409/04/14 Readily isolated bispecific antibodies with native immunoglobulin format
1652014024350408/28/14 Antibodies comprising chimeric constant domains
1662014024546608/28/14 Humanized t cell co-receptor mice
1672014024546708/28/14 Genetically modified major histocompatibility complex mice
1682014024546808/28/14 Non-human animals with modified immunoglobulin heavy chain sequences
1692014022002308/07/14 Method of treating osteoarthritis with an antibody to ngf
1702014021377307/31/14 Adam6 mice
1712014019655007/17/14 Systems and devices for sample handling
1722014019976107/17/14 Promoter-regulated differentiation-dependent self-deleting cassette
1732014019340207/10/14 Anti-pdgfr-beta antibodies and uses thereof
1742014019459707/10/14 Modified chimeric polypeptides with improved pharmacokinetic properties
1752014018990007/03/14 Mirna-regulated differentiation-dependent self-deleting cassette
1762014017887906/26/14 Compositions and methods for modifying cells
1772014017990306/26/14 High affinity human antibodies to human protease-activated receptor 2
1782014015470106/05/14 Humanized fc gamma r mice
1792014015568906/05/14 Methods of modifying genes in eukaryotic cells
1802014015744506/05/14 Low affinity fcgr deficient mice
1812014013797805/22/14 System and methods for use in dispensing biopharmaceutical materials
1822014013416905/15/14 Methods of treating ovarian cancer with dll4 antagonists
1832014013418905/15/14 Anti-prokineticin receptor (prokr) antibodies and uses thereof
1842014013471905/15/14 Recombinant cell surface capture proteins
1852014013727505/15/14 Hybrid light chain mice
1862014013019305/08/14 Mice that make vl binding proteins
1872014013019405/08/14 Mice that make vl binding proteins
1882014012010905/01/14 Human antibodies to human tnf-like ligand 1a (tl1a)
1892014011293004/24/14 Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1902014009931204/10/14 Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
1912014008829503/27/14 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
1922014008276003/20/14 Non-human animals expressing ph-sensitive immunoglobulin sequences
1932014007256303/13/14 Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
1942014007258303/13/14 Methods for treating atopic dermatitis by administering an il-4r antagonist
1952014007297903/13/14 Isolating cells expressing secreted proteins
1962014007298003/13/14 Isolating cells expressing secreted proteins
1972014007301003/13/14 Methods of modifying eukaryotic cells
1982014007558603/13/14 Parental cell lines for making cassette-free f1 progeny
1992014005690302/27/14 Human antibodies to gfr alpha 3 and methods of use thereof
2002014005690702/27/14 Anti-asic1 antibodies and uses thereof
2012014004473002/13/14 Anti-pcsk9 antibodies with ph-dependent binding characteristics
2022014004106802/06/14 Methods of modifying eukaryotic cells
2032014003333601/30/14 Methods of modifying eukaryotic cells
2042014003333701/30/14 Methods of modifying eukaryotic cells
2052014002363701/23/14 Methods of modifying eukaryotic cells
2062014001722801/16/14 Humanized light chain mice
2072014001722901/16/14 Methods of modifying eukaryotic cells
2082014001723801/16/14 Methods of modifying eukaryotic cells
2092014001769501/16/14 Isolating cells expressing secreted proteins
2102014001778101/16/14 Methods of modifying eukaryotic cells
2112014001778201/16/14 Methods for modifying eukaryotic cells
2122014001852201/16/14 Methods of modifying eukaryotic cells
2132014002012401/16/14 Methods of modifying eukaryotic cells
2142014002012501/16/14 Methods of modifying eukaryotic cells
2152014001345601/09/14 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
2162014001345701/09/14 Methods of modifying eukaryotic cells
2172013034453812/26/13 Human antibodies to the glucagon receptor
2182013034010412/19/13 Humanized il-7 rodents
2192013033305712/12/13 Humanized non-human animals with restricted immunoglobulin heavy chain loci
2202013032326012/05/13 Stabilized formulations containing anti-dll4 antibodies
2212013032326112/05/13 Purified antibody composition
2222013032378812/05/13 Production cell line enhancers
2232013032379012/05/13 Human lambda light chain mice
2242013032379112/05/13 Restricted immunoglobulin heavy chain mice
2252013032664712/05/13 Human lambda light chain mice
2262013030967011/21/13 Nuclease-mediated targeting with large targeting vectors
2272013031212811/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
2282013031212911/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
2292013029509711/07/13 Human antibodies to fel d1 and methods of use thereof
2302013028075810/24/13 Fusion polypeptides capable of activating receptors
2312013027307010/17/13 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
2322013026657410/10/13 Human antibodies to human angiopoietin-like protein 4
2332013025987610/03/13 Anti-hla-b*27 antibodies and uses thereof
2342013025988110/03/13 Fusion polypeptides capable of activating receptors
2352013026105610/03/13 Vegf antagonist formulations
2362013025172809/26/13 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
2372013025491109/26/13 Adam6 mice
2382013024377509/19/13 Multispecific antigen-binding molecules and uses thereof
2392013024378409/19/13 Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
2402013024723409/19/13 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
2412013024723509/19/13 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
2422013024723609/19/13 Non-human animals expressing ph-sensitive immunoglobulin sequences
2432013023053109/05/13 Human antibodies to clostridium difficile toxins
2442013023053309/05/13 Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
2452013021654708/22/13 Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
2462013020949208/15/13 Anti-tie2 antibodies and uses thereof
2472013021013708/15/13 Methods of modifying eukaryotic cells
2482013021271908/15/13 Humanized rodents that express heavy chain containing vl domains
2492013019587808/01/13 Anti-asic1 antibodies and uses thereof



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###